retatrutide clinical data Retatrutide—A Game Changer in Obesity Pharmacotherapy Phase III retatrutide study demonstrates

It breaks down almost instantly

Possible concerns may include nausea, vomiting, diarrhea, constipation, appetite suppression, dehydration, fatigue, gallbladder concerns, blood sugar changes, excessive weight loss, and loss of lean muscle if weight drops too quickly

One way the gut microbiome impacts our well-being is by producing GLP-1

Moreover, expanding indications aims to explore new markets

Sign Up Quick Summary Retatrutide is an investigational triple-hormone receptor agonist that targets GLP-1, GIP, and glucagon pathways simultaneously, potentially offering enhanced benefits for women with PCOS who struggle with weight management and insulin resistance

Woodward, Effects of dulaglutide and insulin glargine on estimated glomerular filtration rate in a real-world setting